<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710902</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/53/2017</org_study_id>
    <secondary_id>TYH2016127</secondary_id>
    <nct_id>NCT03710902</nct_id>
  </id_info>
  <brief_title>Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke</brief_title>
  <acronym>CARDIOSTROKE</acronym>
  <official_title>Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jukka Putaala</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital District of Helsinki and Uusimaa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CARDIOSTROKE is a randomized trial comparing mobile-device assisted control of
      hypertension together with screening of occult atrial fibrillation to standard care in
      patients with recent ischemic stroke or transient ischemic attack.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) and hypertension are among the main treatable risk factors for
      ischemic stroke and transient ischemic attack (TIA). Detecting paroxysmal atrial fibrillation
      in stroke patients is challenging, but highly relevant since anticoagulation can effectively
      reduce the risk of recurrent strokes. Furthermore, hypertension remains poorly controlled
      even after stroke despite multiple available treatment options. In the CARDIOSTROKE trial,
      the investigators aim to randomize 405 patients with recent ischemic stroke or TIA into (1)
      standard diagnostic work-up, follow-up and treatment (control group) and (2) 3-week ECG
      monitoring to detect occult AF and self-monitoring of blood pressure with
      mobile-device-assisted self-titration of antihypertensive medication (intervention group).
      Randomization will occur 2:1 into control and intervention groups. The co-primary outcomes
      include (1) incidence of new-onset AF and (2) difference in the mean blood pressure at
      12-months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Clinical endpoints will be assessed according to PROBE principles, i.e. outcomes assessors are masked to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with New Atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>New diagnosis of atrial fibrillation (&gt;30 s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in systolic/diastolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with New Cardiovascular Events within 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Any of stroke, myocardial infarction, revascularization, or cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with New Cardiovascular Events within 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Any of stroke, myocardial infarction, revascularization, or cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Costs</measure>
    <time_frame>36 months</time_frame>
    <description>Total direct healthcare costs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events related to ECG monitoring, blood pressure home monitoring, and mobile-device assisted self-adjustment of blood pressure medication according to a pre-specified protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Severe Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Severe adverse event related to mobile-device assisted self-adjustment of blood pressure medication according to a pre-specified protocol.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <condition>Empowerment</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard diagnostic work-up, follow-up, and treatment of hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECG monitoring for 3 weeks</intervention_name>
    <description>A 3-week continuous ECG monitoring to detect occult AF.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self-monitoring of BP and self-titration of antihypertensive medication</intervention_name>
    <description>One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke or transient ischemic attack (ABCD2 score ≥3)

          -  Age ≥40 years

          -  Informed consent from the patient or legal representative

        Exclusion Criteria:

          -  Known high-risk source of cardioembolism

          -  Known indication for anticoagulation

          -  Non-compliance to study interventions as judged by the investigator

          -  Serious condition hampering the study conduct
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tuomas Lumikari, MD</last_name>
    <phone>+35894711</phone>
    <email>tuomas.lumikari@helsinki.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anu Eräkanto</last_name>
    <email>anu.erakanto@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terhi Saarikoski, RN</last_name>
      <phone>+35894711</phone>
      <email>terhi.saarikoski@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Tuomo Nieminen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jukka Putaala, A/Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuomas Lumikari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital District of Helsinki and Uusimaa</investigator_affiliation>
    <investigator_full_name>Jukka Putaala</investigator_full_name>
    <investigator_title>Head of Stroke Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

